Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Once-Daily ART Regimens in HIV-TB Coinfection
NCT00332306Phase 3Unknown
- Sponsor
- National Institute for Research in Tuberculosis
- Start
- Jun 2006
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in human immunodeficiency virus type 1 infection (HIV-1) comparing Efavirenz Arm with Nevirapine Arm (2 arms). Primary endpoints: Suppression of Viral load to < 400 copies/ml at 6 months and Viral load < 400 copies/ml at 24 months. Status: unknown.
02
Drugs
efavirenznevirapine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00332306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00332306.